Breaking News Instant updates and real-time market news.

GTHX

G1 Therapeutics

$22.57

-0.04 (-0.18%)

04:55
05/21/19
05/21
04:55
05/21/19
04:55

G1 Therapeutics management to meet with BTIG

Meeting to be held in San Francisco, CA on May 21 hosted by BTIG.

  • 21

    May

  • 21

    May

  • 12

    Jun

GTHX G1 Therapeutics
$22.57

-0.04 (-0.18%)

01/23/19
JPMS
01/23/19
DOWNGRADE
Target $41
JPMS
Neutral
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded G1 Therapeutics to Neutral and lowered his price target for the shares to $41 from $59. The analyst made a host of rating changes in the smid cap Biotech space following his firm's Healthcare Conference.
01/23/19
JPMS
01/23/19
DOWNGRADE
Target $41
JPMS
Neutral
JPMorgan downgrades G1 Therapeutics with lack of first half catalysts
JPMorgan analyst Anupam Rama downgraded G1 Therapeutics to Neutral from Overweight and cut his price target for the shares to $41 from $59. The downgrade is largely dictated by key clinical data being weighted towards the second half of 2019, Rama tells investors in a research note. As such, he sees the stock's catalysts more in the summer / second half of the year timeframe.
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
G1 Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started G1 Therapeutics with a Buy rating and $55 price target.
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
B. Riley FBR starts G1 Therapeutics with Buy rating, $55 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. G1's lead candidate, trilaciclib, has the potential to address myelotoxicity and improve overall survival in chemotherapy-associated treatment regimens, Polishetty tells investors in a research note. Further, Lerociclib, although fourth to market, demonstrates potential to be best in class given its clean safety profile thus far adds the analyst. She also believes G1T48 allows for competitive pricing when both lerociclib and G1T48 hit the market.

TODAY'S FREE FLY STORIES

WE

We Company

$0.00

(0.00%)

07:19
06/19/19
06/19
07:19
06/19/19
07:19
Periodicals
WeWork's lease liabilities could be an issue amid IPO plans, WSJ reports »

WeWork's large lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDB

MongoDB

$166.49

1.27 (0.77%)

07:19
06/19/19
06/19
07:19
06/19/19
07:19
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

PAYC

Paycom

$222.05

2.4 (1.09%)

07:18
06/19/19
06/19
07:18
06/19/19
07:18
Initiation
Paycom initiated  »

Cantor starts Paycom at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$357.12

6.98 (1.99%)

07:17
06/19/19
06/19
07:17
06/19/19
07:17
Recommendations
Netflix analyst commentary  »

Netflix CFO still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

  • 17

    Jul

MYGN

Myriad Genetics

$24.17

-0.6 (-2.42%)

, AZN

AstraZeneca

$40.94

0.96 (2.40%)

07:16
06/19/19
06/19
07:16
06/19/19
07:16
Hot Stocks
Myriad receives second insurance reimbursement decision for BRACAnalysis »

Myriad Genetic…

MYGN

Myriad Genetics

$24.17

-0.6 (-2.42%)

AZN

AstraZeneca

$40.94

0.96 (2.40%)

MRK

Merck

$84.49

1.19 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

  • 13

    Nov

ADBE

Adobe

$276.80

1.21 (0.44%)

07:15
06/19/19
06/19
07:15
06/19/19
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$51.58

-0.44 (-0.85%)

07:14
06/19/19
06/19
07:14
06/19/19
07:14
Upgrade
Six Flags rating change  »

Six Flags upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:14
06/19/19
06/19
07:14
06/19/19
07:14
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Recommendations
Ventas analyst commentary  »

Ventas price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Sorrento Therapeutics says Phase 1b resiniferatoxin trial met day 84 goals »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Ventas Investor Day presentation sees 'core portfolio growth' through 2024 »

Sees 5%-7% FFO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USCR

U.S. Concrete

$47.49

-0.78 (-1.62%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Conference/Events
U.S. Concrete management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 13

    Nov

FCAU

Fiat Chrysler

$13.49

0.11 (0.82%)

07:12
06/19/19
06/19
07:12
06/19/19
07:12
Initiation
Fiat Chrysler initiated  »

Fiat Chrysler reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

NCMI

National CineMedia

$6.44

-0.03 (-0.46%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Upgrade
National CineMedia rating change  »

National CineMedia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MDB

MongoDB

$166.49

1.27 (0.77%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Recommendations
MongoDB analyst commentary  »

MongoDB bulls likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Hot Stocks
Axalta Coating up 14% after announcing review of strategic alternatives »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/19/19
06/19
07:10
06/19/19
07:10
General news
FX Update: The dollar has seen moderate softness »

FX Update: The dollar has…

NBRV

Nabriva Therapeutics

$2.11

0.045 (2.18%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Hot Stocks
Nabriva Therapeutics submits Type A Meeting Request to FDA for CONTEPO »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Upgrade
Adobe rating change  »

Adobe upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:08
06/19/19
06/19
07:08
06/19/19
07:08
Hot Stocks
Sorrento Therapeutics CEO to provide updates on CD38 immunotherapies »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$4.78

-0.02 (-0.42%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Hot Stocks
Intec Pharma's Accordion Pill meets primary endpoint in PK study »

Intec Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$1.82

0.13 (7.69%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRB

Seres Therapeutics

$2.61

0.16 (6.53%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Hot Stocks
Seres Therapeutics provides statement regarding FDA safety alert for FMT use »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$60.46

1.205 (2.03%)

07:04
06/19/19
06/19
07:04
06/19/19
07:04
Hot Stocks
Cubic announces sale of commercial properties in San Diego, Orlando for $46M »

Cubic announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.